دورية أكاديمية
أعرض في EDS

Changing from lipoprotein apheresis to evolocumab treatment lowers circulating levels of arachidonic acid and oxylipins.

التفاصيل البيبلوغرافية
العنوان: Changing from lipoprotein apheresis to evolocumab treatment lowers circulating levels of arachidonic acid and oxylipins.
المؤلفون: Wang C; Medical Department B, Division of Hepatology, Gastroenterology, Oncology, Hematology, Palliative Care, Endocrinology and Diabetes, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, Germany.; Medical Department, Division of Psychosomatic Medicine, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology Cottbus-Senftenberg, Brandenburg Medical School and University of Potsdam, Potsdam, Germany., Kaufmann A; Chair of Food Chemistry, Faculty of Mathematics and Natural Sciences, University of Wuppertal, Wuppertal, Germany., Kampschulte N; Chair of Food Chemistry, Faculty of Mathematics and Natural Sciences, University of Wuppertal, Wuppertal, Germany., Elbelt U; Medical Department B, Division of Hepatology, Gastroenterology, Oncology, Hematology, Palliative Care, Endocrinology and Diabetes, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, Germany.; Medical Department, Division of Psychosomatic Medicine, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology Cottbus-Senftenberg, Brandenburg Medical School and University of Potsdam, Potsdam, Germany.; MVZ Endokrinologikum Berlin, Berlin, Germany., Kassner U; Medical Department, Division of Hepatology and Gastroenterology (including Metabolic Diseases), Campus Virchow Klinikum, Charité-Universitätsmedizin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Steinhagen-Thiessen E; Medical Department, Division of Hepatology and Gastroenterology (including Metabolic Diseases), Campus Virchow Klinikum, Charité-Universitätsmedizin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Pietzner A; Medical Department B, Division of Hepatology, Gastroenterology, Oncology, Hematology, Palliative Care, Endocrinology and Diabetes, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, Germany.; Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology Cottbus-Senftenberg, Brandenburg Medical School and University of Potsdam, Potsdam, Germany., Schmöcker C; Medical Department B, Division of Hepatology, Gastroenterology, Oncology, Hematology, Palliative Care, Endocrinology and Diabetes, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, Germany.; Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology Cottbus-Senftenberg, Brandenburg Medical School and University of Potsdam, Potsdam, Germany., Datta D; Department of Metabolic Medicine, University Hospital Llandough, Cardiff, United Kingdom., Sanpietro T; Lipoapheresis Unit, Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Pisa, Italy., Schebb NH; Chair of Food Chemistry, Faculty of Mathematics and Natural Sciences, University of Wuppertal, Wuppertal, Germany., Weylandt KH; Medical Department B, Division of Hepatology, Gastroenterology, Oncology, Hematology, Palliative Care, Endocrinology and Diabetes, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, Germany.; Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology Cottbus-Senftenberg, Brandenburg Medical School and University of Potsdam, Potsdam, Germany., Rohwer N; Medical Department B, Division of Hepatology, Gastroenterology, Oncology, Hematology, Palliative Care, Endocrinology and Diabetes, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, Germany.; Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology Cottbus-Senftenberg, Brandenburg Medical School and University of Potsdam, Potsdam, Germany.; Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
المصدر: Atherosclerosis plus [Atheroscler Plus] 2024 Feb 12; Vol. 55, pp. 55-62. Date of Electronic Publication: 2024 Feb 12 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 9918249514806676 Publication Model: eCollection Cited Medium: Internet ISSN: 2667-0895 (Electronic) Linking ISSN: 26670895 NLM ISO Abbreviation: Atheroscler Plus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B.V., [2021]-
مستخلص: Background and Aims: Previous studies have shown that lipoprotein apheresis can modify the plasma lipidome and pro-inflammatory and pro-thrombotic lipid mediators. This has not been examined for treatment with protein convertase subtilisin/kexin type 9 inhibitors such as evolocumab, which are increasingly used instead of lipoprotein apheresis in treatment-resistant familial hypercholesterolemia. The aim of this study was to compare the effects of evolocumab treatment and lipoprotein apheresis on the fatty acid profile and on formation of lipid mediators in blood samples.
Methods: We analyzed blood samples from 37 patients receiving either lipoprotein apheresis or evolocumab treatment as part of a previous study. Patients were stratified according to receiving lipoprotein apheresis (n = 19) and evolocumab treatment (n = 18). Serum fatty acid analysis was performed using gas chromatography flame ionization detection and plasma oxylipin analysis was done using liquid chromatography tandem mass spectrometry.
Results: Changing from lipoprotein apheresis to evolocumab treatment led to lower levels of omega-6 polyunsaturated fatty acid (n-6 PUFA) including arachidonic acid, dihomo-γ-linolenic acid and linoleic acid. Moreover, several n-6 PUFA-derived oxylipins were reduced after evolocumab treatment.
Conclusions: Given that arachidonic acid, either directly or as a precursor, is associated with the development of inflammation and atherosclerosis, evolocumab-mediated reductions of arachidonic acid and its metabolites might have an additional beneficial effect to lower cardiovascular risk.
Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: This study was supported by Amgen GmbH (Karsten-Henrich Weylandt). The remaining authors disclose no conflicts.
(© 2024 The Authors.)
References: Ther Adv Endocrinol Metab. 2010 Apr;1(2):51-60. (PMID: 23148150)
Nutrients. 2019 Feb 09;11(2):. (PMID: 30744123)
J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 15;783(2):383-9. (PMID: 12482481)
J Vasc Res. 2013;50(5):372-82. (PMID: 23969947)
J Am Coll Cardiol. 2014 Oct 7;64(14):1418-26. (PMID: 25277610)
J Nutr Metab. 2012;2012:539426. (PMID: 22570770)
Lancet. 2007 Mar 31;369(9567):1090-8. (PMID: 17398308)
Eicosanoids. 1992;5(1):17-22. (PMID: 1419075)
Atheroscler Suppl. 2017 Nov;30:193-199. (PMID: 29096838)
Anal Bioanal Chem. 2016 Jan;408(1):97-105. (PMID: 26511226)
Atherosclerosis. 2002 May;162(1):187-91. (PMID: 11947913)
Atherosclerosis. 2004 Jul;175(1):145-50. (PMID: 15186959)
Hypertension. 2001 Feb;37(2):334-8. (PMID: 11230294)
Arterioscler Thromb Vasc Biol. 2005 Nov;25(11):2301-7. (PMID: 16166569)
Pharmacol Res. 2019 Jun;144:336-342. (PMID: 31028904)
Front Pharmacol. 2019 Mar 07;10:169. (PMID: 30899221)
Clin Res Cardiol Suppl. 2019 Apr;14(Suppl 1):33-38. (PMID: 30838552)
J Biol Chem. 2004 Mar 5;279(10):9440-50. (PMID: 14676201)
J Clin Invest. 1997 Mar 1;99(5):888-93. (PMID: 9062346)
Thromb Res. 2016 Aug;144:192-201. (PMID: 27393924)
J Clin Lipidol. 2019 Nov - Dec;13(6):901-909.e3. (PMID: 31759938)
Atheroscler Suppl. 2013 Jan;14(1):93-9. (PMID: 23357149)
Anal Biochem. 2001 May 15;292(2):234-44. (PMID: 11355856)
Pharmacol Ther. 2018 Mar;183:177-204. (PMID: 29080699)
Signal Transduct Target Ther. 2021 Feb 26;6(1):94. (PMID: 33637672)
Anal Bioanal Chem. 2023 Feb;415(5):913-933. (PMID: 36683060)
J Endocrinol Invest. 2013 Jun;36(6):385-9. (PMID: 23095287)
Atherosclerosis. 2016 Jun;249:30-5. (PMID: 27062407)
Drugs. 2015 Sep;75(13):1567-73. (PMID: 26323342)
Biochim Biophys Acta. 1994 Dec 30;1196(2):154-64. (PMID: 7841179)
BMC Biochem. 2005 Mar 24;6:5. (PMID: 15790399)
Br J Clin Pharmacol. 2013 Mar;75(3):645-62. (PMID: 22765297)
Artif Organs. 2014 Feb;38(2):135-41. (PMID: 23889507)
N Engl J Med. 2017 May 4;376(18):1713-1722. (PMID: 28304224)
Atherosclerosis. 1997 May;131(1):97-106. (PMID: 9180250)
Anal Chim Acta. 2018 Dec 11;1037:63-74. (PMID: 30292316)
Clin Res Cardiol Suppl. 2015 Apr;10:2-7. (PMID: 25686595)
Prog Lipid Res. 2019 Jan;73:28-45. (PMID: 30472260)
J Diabetes Investig. 2019 May;10(3):639-649. (PMID: 30251333)
N Engl J Med. 2019 Jan 3;380(1):11-22. (PMID: 30415628)
Diabetes Care. 2005 Sep;28(9):2312-9. (PMID: 16123510)
Prog Lipid Res. 2016 Jul;63:132-52. (PMID: 27216485)
فهرسة مساهمة: Keywords: Arachidonic acid; Cardiovascular disease; Evolocumab; Lipid mediator; Lipoprotein apheresis; Oxylipin; Polyunsaturated fatty acid
تواريخ الأحداث: Date Created: 20240223 Latest Revision: 20240224
رمز التحديث: 20240224
مُعرف محوري في PubMed: PMC10881432
DOI: 10.1016/j.athplu.2024.01.005
PMID: 38390468
قاعدة البيانات: MEDLINE
الوصف
تدمد:2667-0895
DOI:10.1016/j.athplu.2024.01.005